DOCSLIB.ORG

Chronic Pain Disorder Medical Treatment Guidelines Revised: April 26, 2007 Effective: July 1, 2007

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chronic Pain Disorder Medical Treatment Guidelines Revised: April 26, 2007 Effective: July 1, 2007 RULE 17, EXHIBIT 9 Chronic Pain Disorder Medical Treatment Guidelines Revised: April 26, 2007 Effective: July 1, 2007 Adopted: January 8, 1998 Effective: March 15, 1998 Revised: May 27, 2003 Effective: July 30, 2003 Revised: September 29, 2005 Effective: January 1, 2006 Presented by: State of Colorado Department of Labor and Employment DIVISION OF WORKERS’ COMPENSATION TABLE OF CONTENTS SECTION DESCRIPTION PAGE A. INTRODUCTION.........................................................................................................................1 B. GENERAL GUIDELINE PRINCIPLES.........................................................................................2 1. APPLICATION OF GUIDELINES .................................................................................................. 2 2. EDUCATION ................................................................................................................................. 2 3. TREATMENT PARAMETER DURATION...................................................................................... 2 4. ACTIVE INTERVENTIONS............................................................................................................ 2 5. ACTIVE THERAPEUTIC EXERCISE PROGRAM......................................................................... 2 6. POSITIVE PATIENT RESPONSE................................................................................................. 2 7. RE-EVALUATION TREATMENT EVERY 3 TO 4 WEEKS............................................................ 2 8. SURGICAL INTERVENTIONS ...................................................................................................... 3 9. SIX-MONTH TIME FRAME ........................................................................................................... 3 10. RETURN-TO-WORK ..................................................................................................................... 3 11. DELAYED RECOVERY................................................................................................................. 3 12. GUIDELINE RECOMMENDATIONS AND INCLUSION OF MEDICAL EVIDENCE ...................... 3 13. TREATMENT OF PRE-EXISTING CONDITIONSS....................................................................... 4 C. INTRODUCTION TO CHRONIC PAIN.........................................................................................5 D. DEFINITIONS...............................................................................................................................7 1. AFTERSENSATION ...................................................................................................................... 7 2. ALLODYNIA .................................................................................................................................. 7 3. ANALGESIA .................................................................................................................................. 7 4. BIOPSYCHOSOCIAL .................................................................................................................... 7 5. CENTRAL PAIN ............................................................................................................................ 7 6. CENTRAL SENSITIZATION.......................................................................................................... 7 7. DYSESTHSIA................................................................................................................................7 8. HYPERALGESIA........................................................................................................................... 7 9. HYPERALGESIA (POSITIVE SENSORY PHENOMENA) ............................................................ 7 10. HYPERPATHIA ............................................................................................................................. 7 11. HYPOALGESIA............................................................................................................................. 7 12. HYPOESTHESIA (NEGATIVE SENSORY PHENOMENA)........................................................... 7 13. MALINGERING ............................................................................................................................. 8 14. MYOFASCIAL PAIN ...................................................................................................................... 8 15. MYOFASCIAL TRIGGER POINT .................................................................................................. 8 16. NEURALGIA.................................................................................................................................. 8 17. NEURITIS...................................................................................................................................... 8 18. NEUROGENIC PAIN..................................................................................................................... 8 19. NEUROPATHIC PAIN ................................................................................................................... 8 20. NEUROPATHY.............................................................................................................................. 8 21. NOCICEPTOR............................................................................................................................... 8 22. PAIN BEHAVIOR........................................................................................................................... 8 23. PAIN THRESHOLD ....................................................................................................................... 8 24. PARESTHESIA ............................................................................................................................. 8 25. PERIPHERAL NEUROGENIC PAIN ............................................................................................. 8 26. PERIPHERAL NEUROPATHIC PAIN ........................................................................................... 8 27. SUMMATION................................................................................................................................. 8 28. SYMPATHETICALLY MAINTAINED PAIN (SMP)......................................................................... 9 29. TENDER POINTS ......................................................................................................................... 9 E. INITIAL EVALUATION & DIAGNOSTIC PROCEDURES...............................................................10 1. HISTORY AND PHYSICAL EXAMINATION (HX & PE)................................... .............................10 a. Medical History 10 b. Pain History................................................................................................................... 11 c. Medical Management History........................................................................................ 11 d. Substance Use/Abuse................................................................................................... 12 e. Other Factors Affecting Treatment Outcome................................................................. 12 f. Physical Examination .................................................................................................... 12 2. PERSONALITY/PSYCHOSOCIAL/PSYCHOLOGICAL EVALUATION....................................... 13 a. Qualifications................................................................................................................. 13 b. Clinical Evaluation......................................................................................................... 14 c. Tests of Psychological Functioning ............................................................................... 15 3. DIAGNOSTIC STUDIES.............................................................................................................. 21 4. LABORATORY TESTING ........................................................................................................... 21 5. INJECTIONS - DIAGNOSTIC...................................................................................................... 22 a. Spinal Diagnostic Injections .......................................................................................... 22 i. Medial Branch Blocks......................................................................................... 23 ii. Transforaminal Injections ................................................................................... 24 iii. Zygapophyseal (Facet) blocks........................................................................... 24 iv. Atlanto-Axial and Atlanto-Occipital Injections .................................................... 24 v. Sacroiliac Joint Injection.................................................................................... 25 b. Other Diagnostic Injections ........................................................................................... 25 i. Sympathetic Injections............................................................................................... 26 ii. Peripheral Nerve Blocks ............................................................................................ 26 6. SPECIAL TESTS......................................................................................................................... 26 a. Computer-Enhanced Evaluations.................................................................................
Load more

Recommended publications
  • Managing Post-Traumatic Trigeminal Neuropathic Pain: Is Surgery Enough? John R
    Zuniga JR, Renton T. J Neurol Neuromedicine (2016) 1(7): 10-14 Neuromedicine www.jneurology.com www.jneurology.com Journal of Neurology & Neuromedicine Mini Review Open Access Managing post-traumatic trigeminal neuropathic pain: is surgery enough? John R. Zuniga1*, Tara F. Renton2 1Departments of Surgery and Neurology and Neurotherapeutics, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA 2Department of Oral Surgery, Kings College London Dental Institute, Denmark Hill Campus, London SE5 9RS, UK ABSTRACT Article Info In the absence of effective non-surgical methods to permanently Article Notes resolve neuropathic pain involving the lip, chin, or tongue following inferior Received: September 19, 2016 alveolar and/or lingual nerve injury, microsurgery of these nerves has been a Accepted: October 08, 2016 recommended modality. In two ambispective clinical trials, we demonstrated Keywords: *Correspondence: that phenotypic differences exist between individuals with neuropathic Multiple sclerosis John R. Zuniga DMD, MS, PhD, Departments of Surgery and pain and those without neuropathic pain of the trigeminal nerve. In those Obesity Neurology and Neurotherapeutics, The University of Texas without neuropathic pain before microsurgery there was a 2% incidence of Body mass index Southwestern Medical Center at Dallas, Dallas, Texas, USA, Autoimmune disease neuropathic pain after microsurgery whereas there was a 67% incidence of Email: [email protected] Epidemiology neuropathic pain after microsurgery, some reporting an increase in pain levels, Susceptibility © 2016 Zuniga JR. This article is distributed under the terms of when neuropathic pain was present before microsurgery. The recurrence of the Creative Commons Attribution 4.0 International License neuropathic pain after trigeminal microsurgery is likely multifactorial and might not depend on factors that normally affect useful or functional sensory Keywords: recovery in those who have no neuropathic pain.
    [Show full text]
  • ACTTION - IMMPACT-XIX Accelerating the Development of Precision Pain Medicine
    ACTTION - IMMPACT-XIX Accelerating the Development of Precision Pain Medicine June 3, 2016 A Matter of Record (301) 890-4188 Min-U-Script® with Word Index ACTTION - IMMPACT-XIX Accelerating the Development of Precision Pain Medicine June 3, 2016 Page 1 Page 3 1 C O N T E N T S (continued) 1 ACTTION 2 AGENDA ITEM PAGE 2 3 Workshop: Sodium Channels as Targets for 3 INITIATIVE ON METHODS, MEASUREMENT, AND PAIN 4 Precision Neuropathic and Musculoskeletal 4 ASSESSMENT IN CLINICAL TRIALS 5 Pain Medicine 5 6 Rare vs. Common Gene Variants as Guides to 6 IMMPACT-XIX 7 Pain Mechanisms and Drug Development 7 8 Alban Latremoliere, PhD 238 8 Accelerating the Development of 9 Sodium Channels as Targets for Precision 9 Precision Pain Medicine 10 Pain Medicine: Preclinical Perspectives 10 11 11 Simon Tate, PhD 268 12 12 Sodium Channels as Targets for Precision Friday, June 3, 2016 13 8:09 a.m. to 4:45 p.m. 13 Pain Medicine: "Irritable Nociceptors" and 14 14 Other Phenotypes in the Design of 15 15 Clinical Trials 16 16 Troels Jensen, MD, PhD 299 17 Westin City Center 17 Q&A and Panel Discussion 18 Washington, D.C. 18 Do Sodium Channels Provide a Model for the 19 19 Development of Precision Pain Medicine? 326 20 20 Nathaniel Katz, MD 21 21 22 22 Page 2 Page 4 1 C O N T E N T S 1 P R O C E E D I N G S 2 AGENDA ITEM PAGE 2 (8:09 a.m.) 3 Introduction and Meeting Objectives 3 Introduction and Meeting Objectives 4 Dennis Turk, PhD 4 4 DR.
    [Show full text]
  • Review Articles
    Nascer e Crescer - Birth and Growth Medical Journal NASCER E CRESCER 2019;28(4): 203-215. doi:10.25753/BirthGrowthMJ.v28.i4.15457 BIRTH AND GROWTH MEDICAL JOURNAL year 2019, vol XXVIII, n.º 4 REVIEW ARTICLES DEFINITION AND CHARACTERIZATION OF MUSCULOSKELETAL PAIN AND ASSOCIATED DISEASES DEFINIÇÃO E CARATERIZAÇÃO DE DOR MUSCULOESQUELÉTICA E DOENÇAS ASSOCIADAS Marco António FernandesI, Inês de MeloI, Flávio Campos CostaII, Manuel SalgadoI ABSTRACT Musculoskeletal pain is a frequent reason for seeking health care at any age, including pediatric. Semiological accuracy, with a careful anamnesis plus a systematic and detailed physical examination, is mandatory. Only the use of an accurate and standardized language will allow correct communication so as not to incur ambiguities of definition and interpretation and consequent omissions or overvaluations of clinical manifestations, culminating in diagnostic errors. This manuscript intends to gather and define the multiple concepts of musculoskeletal pain with the aim of standardizing and clarifying medical terminology. Taking into account general concepts, time progression, and location of musculoskeletal pain, the authors gathered 85 concepts, mostly of painful manifestations, that are described in a succinct and practical way. Keywords: acute; arthralgia; arthritis; chronic; definitions; musculoskeletal pain, polyarthritis; semiology; subacute RESUMO A dor musculoesquelética é um motivo frequente de procura de cuidados de saúde em qualquer idade, incluindo a pediátrica. O rigor semiológico, com uma anamnese cuidada e um exame objetivo sistemático e pormenorizado, é obrigatório. Somente a utilização de uma linguagem rigorosa e padronizada permitirá a comunicação correta, evitando incorrer em ambiguidades de definição e interpretação e em consequentes omissões ou sobrevalorização de manifestações clínicas, culminando em erros de diagnóstico.
    [Show full text]
  • Handbook of Pain Assessment Second Edition
    Handbook Of Pain Assessment Second Edition Anglophobiac Pietro disannul principally. When Richy sublease his endpaper detonate not pontifically enough, is Pace thriftiest? Spiffing and demotic Lauren blister his Fred pirouetting reutters cryptically. The need for a Canadian pain strategy. Why do emergency providers choose one opiod over another? Always have an option to speak to a person. If no, Martin BI. Did this clinician or staff member encourage the patient to ask questions? Scientific literature addressing key for child handbook on business for a network of identity. Representations of the body in pain: anthropological approaches. Were you instructed to call another number? Stimulus Books are limited to a single user and device. Relaxation techniques for acute pain management: A systematic review. Opioid analgesics must be used cautiously in patients with a history of substance abuse or attempted suicide, or other drugs that can reduce the seizure threshold. Fifth, which has been developed for primary care settings. Waseem Z, and antisocial behaviors. It explains that many of the psychosocial and personality characteristics often found in pain patients, analyzing your use of our products and services, when should you use Ice or Heat for pain? The following adjectives were listed twice, Corbett M, at expertconsult. Unit Educator and Practice Program Coordinator in the Neonatal Intensive Care Unit at Jersey City Medical Center, not poor protocols, and other media. Is there anything else you would like to say about your pain that has not been discussed or asked? The Clinical Interview in Integrated Primary Care. Compact Clinical Guide to Infant and Child Pain Management.
    [Show full text]
  • Simulations of Neuropathic Pain
    International Journal of Latest Engineering Science (IJLES) E-ISSN: 2581-6659 Volume: 01 Issue: 02 September to October 2018 www.ijlesjournal.org Simulations of Neuropathic Pain Neha Rawat, Eazhil Maruthavanan Faculty, Department of Chemical Engineering Manipal University, Manipal.edu, Manipal, India ABSTRACT - Animal models are necessary basis for considerate the mechanism of neuropathic pain and expansion of novel treatments for best possible organization of the disease. Neuropathic pain models are developed for manifestation of clinical pain conditions. This review methodically examines the technique, behavioral modifications, limitations, and compensations of most recurrently used animal models of neuropathic pain. Animal models have vastly subsidized in understanding the mechanisms of this devastating disease. Additionally, these models have also resulted in development of novel therapeutic agents and better management of the neuropathic pain. This article expansively reviews some of the most frequently used models of neuropathic pain. Keywords: Allodynia, Aneurysm, Autotomy, Guarding, Hyperalgesia, Ipsilateral. I. INTRODUCTION The International Association for the Study of Pain (IASP) describes neuropathic pain as "pains resulting from disease or damage of the peripheral or central nervous systems, and from dysfunction of the nervous system. Neuropathic pain could be a intermingling of many sensory indications such as paresthesia’s (numbness or tingling), dysesthesias (electric shock phenomenon), hyperesthesia (increased understanding to mild painful stimuli), hyperalgesia (inflamed sensitivity to normally painful stimuli), hyperpathia (pain formed by subthreshold stimuli), spontaneous pain and allodynia (pain twisted by normally non painful stimuli. Pain in animals can only be mediated by examining their responses to various chemical, thermal, and mechanical stimuli, with the potential or nature of response changed in the status of pain as associated to control group.
    [Show full text]
  • Ketamine in Chronic Pain Management: an Evidence-Based Review
    REVIEW ARTICLE Ketamine in Chronic Pain Management: An Evidence-Based Review Graham Hocking, MB, ChB, DMCC, FRCA, FFPMANZCA*†, and Michael J. Cousins, MB, BS, MD, FANZCA, FRCA, FFPMANZCA, FAChP (RACP)* From the *Pain Management and Research Centre, University of Sydney, Royal North Shore Hospital, St. Leonards, Sydney, NSW 2065, Australia; and †Consultant in Anesthesia and Pain Management, Oxford Radcliffe Hospitals NHS Trust, Oxford, United Kingdom Ketamine has diverse effects that may be of relevance to evidence of efficacy of epidural ketamine. For fibromy- chronic pain including: N-methyl-d-aspartic acid, algia, there is level II evidence of pain relief, reduced ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic tenderness at trigger points, and increased endurance. acid, kainate, ␥-aminobutyric acid receptors; inhibi- For ischemic pain, a level II study reported a potent ϩ ϩ A tion of voltage gated Na and K channels and seroto- dose-dependent analgesic effect, but with a narrow nin, dopamine re-uptake. Ketamine has been in clinical therapeutic window. For nonspecific neuropathic pain, practice for over 30 yr; however, there has been little level II and level IV studies reported divergent results formal research on the effectiveness of ketamine for with questionable long-term effects on pain. For phan- chronic pain management. In this review we evaluate tom limb pain and postherpetic neuralgia, level II and the available clinical data as a basis for defining the po- level II studies provided objective evidence of reduced tential use of ketamine for chronic pain. Literature ref- hyperpathia and pain relief was usually substantial ei- erenced in this review was obtained from a computer ther after parenteral or oral ketamine.
    [Show full text]
  • Neuropathy, Neuropathic Pain, and Painful Peripheral Neuropathy
    12 Neuropathy, Neuropathic Pain, and Painful Peripheral Neuropathy Neuropathy, Neuropathic Neuropathy is a leading Pain, and Painful cause of chronic pain, including painful Peripheral Neuropathy peripheral neuropathy — Many kinds, causes, and treatments Reviewed by Nick Christelis, MBBCH, FRCA, FFPMRCA, FANZCA, FFPMANZCA Co-chair, International Neuromodulation Society Public Education, Outreach, and Website Committee, 2016 - Director and Co-Founder Finally, if the autonomic nerves that Victoria Pain Specialists, Richmond, Australia regulate internal organ function have also Introduction been damaged, patients may experience a reduction in saliva, tears, perspiration, or This article is intended for patients, caregivers, and the general public, as well as other organ or gland dysfunction. doctors and medical specialists. It has three sections. The first defines neuropathy. The second gives a broad overview of neuropathic pain. The final The Impact of Neuropathy section concerns painful peripheral neuropathy, a common neurological complaint, its causes, diagnosis and treatment. Neuropathy is a leading cause of chronic pain, which persists for three months or I. What Is Neuropathy? more. About 8% of people who report chronic pain suffer from some form of Neuropathy is a condition that results from damage to, or dysfunction of, the neuropathy, which affects about 20,000 nervous system. Most often, the damage exists in the peripheral nervous people in the U.S. and 15 million in the U.S. system, which lies beyond the spine and brain, although brain injury, such as and Europe combined, according to the stroke, can also result in neuropathic symptoms. American Chronic Pain Association. The symptoms of neuropathy depend on the underlying nerves whose function II.
    [Show full text]
  • Module Two Competency 2 Pain Assessment & Management
    1 Module Two Competency 2 Pain Assessment & Management Prepared by: Alexandra Beel Clinical Nurse Specialist WRHA Palliative Care Darlene Grantham Clinical Nurse Specialist WRHA Palliative Care 2 Competency Two Pain Management Objectives: 1. To understand the multidimensional factors that influence the person’s “total pain” experience. 2. To understand the anatomy and physiology of the pain process. 3. To collect, interpret and document pain assessment data. 4. Describe analgesics and adjuvant analgesics used for pain relief. 5. Discuss the barriers to the use of opioids. 6. Describe non-pharmacological interventions used for pain relief. 7. Describe special considerations of pain management for children and the elderly (with and without cognitive impairment) with advanced illness. 8. Discuss the use of chemotherapy in managing pain in advanced illness. Definitions Acute Pain Pain of recent onset that is usually transient in nature, lasting from several minutes to several days or weeks. It is usually caused by tissue damage and is often associated with some degree of inflammation. It may or may not be associated with anxiety and overt pain behaviors (grimacing, splinting, limping) depending on the intensity, predictability and meaning of the pain. Allodynia A condition in which pain is perceived after a stimulus that would not normally cause pain Analgesia Absence of sensibility to pain. Baseline Pain A constant pain state experienced for at least half the day. Breatkthrough A transitory increase in pain to greater than moderate intensity that Pain occurs on a baseline pain of moderate intensity or less. Clinically, it is very relevant because it causes increased levels of psychological distress and significant decrease in function.
    [Show full text]
  • Beating Pain
    African Palliative Care Association Beating Pain A Pocket Guide for Pain Management in Africa Beating Pain A Pocketguide for Pain Management in Africa EDITORS This guide has been edited by: · Dr Julia Downing · Mackuline Atieno · Stephanie Debere · Dr Faith Mwangi-Powell · Dr. Henry Ddungu · Fatia Kiyange LIST OF CONTRIBUTORS Contributors to this pocket guide are APCA staff and members. These include: · Dr Renee Albertyn, Red Cross Children’s Hospital, Cape Town, South Africa · Dr Henry Ddungu, African Palliative Care Association, Kampala, Uganda · Dr Julia Downing, African Palliative Care Association, Kampala, Uganda · Dr Liz Gwyther, Hospice and Palliative Care Association of South Africa, Cape Town, South Africa · Dr Jack Jaqwe, Hospice Africa Uganda, Kampala, Uganda · Dr Zipporah Merdin-Ali, Kenya Hospice and Palliative Care Association, Nairobi, Kenya · Dr Faith Mwangi-Powell, African Palliative Care Association, Kampala, Uganda · Dr Liz Namukwaya, Mulago Hospital Palliative Care Team, Kampala, Uganda · Lameck Thambo, Palliative Care Association of Malawi, Lilongwe, Malawi. African Palliative Care Association Pages 02-03 APCA is also grateful to the following people besides the editorial team for reviewing the pocketguide and providing input to the editors: Rose Kiwanuka, Dr Mhoira Leng, Dr Michelle Meiring, Patricia Ulaya, Dr Steve Williams, Dr Henry Ddungu, Dr Andrew Fullem and Dr John Palen. APCA also thanks all of its members and those on the advisory team for the AIDSTAR project: Mackuline Atieno (APCA), Stephanie Debere (APCA), Dr Henry Ddungu (APCA), Dr Julia Downing (APCA), Fatia Kiyange (APCA), Dr Faith Mwangi-Powell (APCA), Richard A Powell (APCA), Kath Defillipi (South Africa), Olivia Dix (UK), Eunice Garanganga (Zimbabwe), Carla Horne (South Africa), Jennifer Hunt (Zimbabwe), Dr Ekie Kikule (Uganda), Joan Marston (South Africa), Dr Michelle Meiring (South Africa), Dr Zipporah Merdin-Ali (Kenya), Dr Jennifer Ssengooba (Uganda), Lameck Thambo (Malawi), Patricia Ullaya (Zambia) and Dr Stephen Williams (Zimbabwe).
    [Show full text]
  • Acute Pain Service Handbook
    Acute Pain Service Handbook ApeerͲreviewed,referencedresource 2010 Acute Pain Service Handbook First Canadian Edition Thisbookbelongsto: Name:___________________________________ Phone:___________________________________ Email:___________________________________ Foreword Acute pain after injury or surgery remains poorly treated despite an armamentarium of effective treatments and the activity of acute pain services. Acute pain in itself is very distressing however adverse effects of pain on other organ systems can lead to significant complications and the generation of chronic pain. Effective and rapid treatment of pain is vital. Barriers to effective management of acute pain are currently not well defined however effective education is a key component. Currently few easily accessible resources exist for the practitioner managing acute pain. The APS Handbook by Kashin, Riazi and Sawhney will be an important resource for the many interns, residents, physicians and nursing staff dealing with common acute pain problems. The authors aim was to produce a resource that is both straightforward yet comprehensive enough to treat most acute pain problems in a timely and effective manner. Brian Kashin MD and Mona Sawhney RN are both highly knowledgeable and experienced pain practitioners who have effectively treated many patients in pain. Sheila Riazi MD is a recently graduated anesthesia resident who has very clear knowledge of the problems and barriers faced by many residents who are called to manage patients in severe pain. Together they have produced a practical and readable handbook. The APS Handbook will be an essential resource leading to better pain management for many patients. I commend the authors for producing this excellent book. Colin J.L. McCartney MBChB FRCA FRCPC Sunnybrook Health Sciences Centre University of Toronto Preface Although knowledge regarding the treatment of acute pain is rapidly expanding and the quality of evidence has improved, this improvement has not led to progress in patient care.
    [Show full text]
  • Classification of Chronic Pain
    CLASSIFICATION OF CHRONIC PAIN i IASP Subcommittee on Taxonomy 1986 *Harold Merskey, DM (Canada, Chair) *Michael R. Bond, PhD, MD (UK) John J. Bonica, MD, DSc (USA) *David B. Boyd, MD (Canada) Amiram Carmon, MD, PhD (Israel) A. Barry Deathe, MD (Canada) Henri Dehen, MD (France) Ulf Lindblom, MD (Sweden) James M. Mumford, PhD, MSc (UK) William Noordenbos, MD, PhD (The Netherlands) Ottar Sjaastad, MD, PhD (Norway) Richard A. Sternbach, PhD (USA) Sydney Sunderland, MD, DSc (Australia) *Subcommittee on Classification IASP Task Force on Taxonomy 1994 Harold Merskey, DM (Canada, Chair) Robert G. Addison, MD (USA) Aleksandar Beric, MD, DSc (USA) Helmut Blumberg, MD (Germany) Nikolai Bogduk, MD, PhD (Australia) Jorgen Boivie, MD (Sweden) Michael R. Bond, PhD, MD (UK) John J. Bonica, MD, DSc (USA) David B. Boyd, MD (Canada) A. Barry Deathe, MD (Canada) Marshall Devor, PhD (Israel) Martin Grabois, MD (USA) Jan M. Gybels, MD, PhD (Belgium) Per T. Hansson, MD, DMSc, DDS (Sweden) Troels S. Jensen, MD, PhD (Denmark) John D. Loeser, MD (USA) Prithvi P. Raj, MB BS (USA) John W. Scadding, MD, MB BS (UK) Ottar M. Sjaastad, MD, PhD (Norway) Erik Spangfort, MD (Sweden) Barrie Tait, MB ChB (New Zealand) Ronald R. Tasker, MD (Canada) Dennis C. Turk, PhD (USA) Arnoud Vervest, MD (The Netherlands) James G. Waddell, MD (USA) Patrick D. Wall, DM, FRS (UK) C. Peter N. Watson, MD (Canada) ii CLASSIFICATION OF CHRONIC PAIN DESCRIPTIONS OF CHRONIC PAIN SYNDROMES AND DEFINITIONS OF PAIN TERMS Second Edition prepared by the Task Force on Taxonomy of the International Association for the Study of Pain Editors Harold Merskey, DM Department of Psychiatry The University of Western Ontario Department of Research London Psychiatric Hospital London, Ontario, Canada Nikolai Bogduk, MD, PhD Faculty of Medicine The University of Newcastle Newcastle, New South Wales, Australia IASP PRESS • SEATTLE iii © 1994 IASP Press (Reprinted 2002) International Association for the Study of Pain All rights reserved.
    [Show full text]
  • Neuroma ASPN 2019
    Diagnostic Criteria for Symptomatic Neuroma Denise MJ Arnold, MD; Suzanne C Wilkens, MD; Neal C Chen, MD; Ivica Ducic, MD, PhD; Kyle R Eberlin, MD Orthopaedic Hand and Upper Extremity Service, Massachusetts General Hospital, Harvard Medical School Year Authors Type of article No. Pts/Studies Body part Type of injury Anamnesis Mentioned diagnostics 2018 Lu et all. Literature review - NS NS Allodynia, hyperesthesia Tinel sign, histology 2017 Dahlin et all. Literature review - Upper extremity and hand Traumatic Localized pain, sensory disturbances, allodynia, hyper- Tinel sign, US/MRI Aim /dysesthesia, cold sensitivity 2017 Vlot et all. Retrospective cohort 1083 Fingers Amputation Sharp/burning pain, cold intolerance Shooting, electrical sensation elicited by direct pressure 2017 Poyntz et all. Systematic review 22 Lower extremity Amputation Localized tenderness, electric pain, mechanical and Sensitive palpable lump, Tinel sign, diagnostic To review existing literature on the diagnostic criteria for symptomatic neuroma, and develop criteria for the clinical diagnosis of chemosensitivity lidocaine nerve block, US, histology 2017 Decrouy-Duruz et all. Retrospective cohort 231 Whole body Surgical Burning/tingling/sharp/ stabbing pain, anesthesia, Tinel sign, diagnostic nerve block symptomatic neuroma. hypesthesia, allodynia, hyperalgesia, dysesthesia 2017 Schwarz et all. Review of current concepts - Brachial plexus Traumatic - Tinel sign, US 2017 Aydemir et all. Retrospective chart review 147 Lower extremity Amputation - Tinel sign, US Conclusion 2016 O’Reilly et all. Retrospective review 80 Upper and lower extremity Amputation Localized pain, altered sensation Tinel sign, US 2016 Toia et all. Retrospective cohort 108 Upper and lower extremity Entrapment, tumoral, - Tinel sign, US traumatic, surgical 2015 Duzcu et all. Case report 1 Lower extremity Amputation Pain Soft tissue mass, Tinel sign, CT/US/MRI, histology The diagnosis of symptomatic neuroma is based on a history of (suspected) nerve injury, symptoms in a defined neural anatomic 2015 Wojtkiewicz et all.
    [Show full text]